“Veins first” versus “artery first” approach for management of mixed arterial venous leg ulcers (MAVLU): Systematic review and meta-analysis

医学 荟萃分析 置信区间 随机对照试验 外科 内科学 心脏病学
作者
Mohammed Alagha,Ahmed Alagha,Aoife Lowery,Stewart R. Walsh
出处
期刊:Phlebology [SAGE]
标识
DOI:10.1177/02683555241282118
摘要

Introduction Mixed Arterial and Venous Leg Ulcers (MAVLU) are challenging. The optimal intervention sequence (artery-first vs vein first) is unclear. This review evaluates current evidence on surgical intervention sequencing. Methods MEDLINE, PUBMED, SCOPUS and EMBASE were searched using the term ‘mixed arterial venous leg ulcers.’ Studies were eligible if they reported ulcer healing outcomes in MAVLU patients. Pooled proportions were calculated by random effects modelling. Results The search yielded 606 studies, eight of which contained sufficient data to include in the analysis. There were no randomized controlled trials. Initial modified compression (MCT) and rescue revascularisation in MAVLU with ABI 0.5 to 0.85 achieved a pooled healing rate of 75% (95% CI 69% to 80%) compared to 79% (95% CI 61% to 93%) in patients with standard VLUs. The pooled rescue revascularisation rate for MAVLU patients with moderate arterial disease was 25% (95% CI 6% to 51%). Patients with severe arterial disease (ABI <0.5) who underwent arterial intervention first were less likely to heal (pooled proportion 40%; 95% confidence interval 16% to 66%). No studies compared either MCT or venous ablation with arterial revascularisation as first-line in patients with moderate arterial disease (ABI 0.5 to 0.85) alone or severe arterial disease (ABI <0.5) alone. There was marked heterogeneity between studies with respect to ulcer healing outcomes reported, definitions of ulcer healing, duration and size of ulcers at presentation, use of adjunct procedures such as skin grafting, unit of measurement (legs vs patients) and duration of follow up. Conclusion A ‘veins first’ approach to MAVLU is plausible but robust data are lacking and should be evaluated in a randomized controlled trial.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yiyin发布了新的文献求助30
刚刚
稚久完成签到,获得积分10
1秒前
今后应助好好采纳,获得10
2秒前
无花果应助ssx采纳,获得10
2秒前
小二郎应助山月采纳,获得10
4秒前
5秒前
李李发布了新的文献求助10
6秒前
感谢帅气的醉蝶转发科研通微信,获得积分50
6秒前
7秒前
8秒前
小二郎应助维尼采纳,获得10
8秒前
愉快敏发布了新的文献求助10
10秒前
10秒前
SciGPT应助天真的邴采纳,获得10
11秒前
丘比特应助天真的邴采纳,获得10
11秒前
Ava应助天真的邴采纳,获得10
11秒前
上官若男应助天真的邴采纳,获得10
11秒前
搜集达人应助天真的邴采纳,获得10
11秒前
感谢sky焰转发科研通微信,获得积分50
11秒前
我是老大应助天真的邴采纳,获得10
12秒前
CodeCraft应助天真的邴采纳,获得30
12秒前
12秒前
Camellia完成签到,获得积分10
12秒前
天行健发布了新的文献求助10
13秒前
14秒前
lu完成签到,获得积分10
14秒前
稳重向南发布了新的文献求助10
14秒前
懵了应助xxxww采纳,获得10
15秒前
15秒前
星辰大海应助愉快敏采纳,获得10
16秒前
16秒前
16秒前
桐桐应助小高采纳,获得10
18秒前
小宝骡发布了新的文献求助10
18秒前
19秒前
大胆夜天发布了新的文献求助10
20秒前
21秒前
21秒前
山月发布了新的文献求助10
22秒前
浮浮完成签到,获得积分10
22秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3149259
求助须知:如何正确求助?哪些是违规求助? 2800349
关于积分的说明 7839651
捐赠科研通 2457913
什么是DOI,文献DOI怎么找? 1308138
科研通“疑难数据库(出版商)”最低求助积分说明 628456
版权声明 601706